Encorafenib
Brand name: Braftovi
Rank #443 of 500 drugs by total cost
$17.6M
Total Cost
1,209
Total Claims
$17.6M
Total Cost
70
Prescribers
$15K
Cost per Claim
0
Beneficiaries
1,227
30-Day Fills
$251K
Avg Cost/Provider
17
Avg Claims/Provider
About Encorafenib
Encorafenib (sold as Braftovi) was prescribed 1,209 times by 70 Medicare Part D providers in 2023, costing the program $17.6M. At $15K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 440 | Metronidazole (Metronidazole) | $18.0M | 405,967 |
| 441 | Rufinamide (Rufinamide) | $18.0M | 8,793 |
| 442 | Istradefylline (Nourianz) | $17.8M | 7,061 |
| 443 | Encorafenib (Braftovi) | $17.6M | 1,209 |
| 444 | Cladribine (Mavenclad) | $17.5M | 228 |
| 445 | Enalapril Maleate (Enalapril Maleate) | $17.5M | 673,317 |
| 446 | Vismodegib (Erivedge) | $17.4M | 1,317 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology